Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 28;15(19):4774.
doi: 10.3390/cancers15194774.

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review

Edoardo Garbo  1 , Benedetta Del Rio  1 , Giorgia Ferrari  1 , Massimiliano Cani  1 , Valerio Maria Napoli  1 , Valentina Bertaglia  1 , Enrica Capelletto  1 , Christian Rolfo  2 , Silvia Novello  1 , Francesco Passiglia  1
Affiliations
Review

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review

Edoardo Garbo et al. Cancers (Basel). .

Abstract

Lung cancer represent the leading cause of cancer mortality, so several efforts have been focused on the development of a screening program. To address the issue of high overdiagnosis and false positive rates associated to LDCT-based screening, there is a need for new diagnostic biomarkers, with liquid biopsy ncRNAs detection emerging as a promising approach. In this scenario, this work provides an updated summary of the literature evidence about the role of non-coding RNAs in lung cancer screening. A literature search on PubMed was performed including studies which investigated liquid biopsy non-coding RNAs biomarker lung cancer patients and a control cohort. Micro RNAs were the most widely studied biomarkers in this setting but some preliminary evidence was found also for other non-coding RNAs, suggesting that a multi-biomarker based liquid biopsy approach could enhance their efficacy in the screening context. However, further studies are needed in order to optimize detection techniques as well as diagnostic accuracy before introducing novel biomarkers in the early diagnosis setting.

Keywords: liquid biopsy; lung cancer; non-coding RNA; screening.

PubMed Disclaimer

Conflict of interest statement

F.P. declared consultant/advisory fees from Astra Zeneca, Janssen, Sanofi, Amgen, Roche, Bristol Myer Squibb, Beigene, and Thermofisher Scientific. S.N. declared speaker bureau/advisor’s fees from Boehringer Ingelheim, Roche, Merck Sharp, Dohme, Amgen, Thermo Fisher Scientific, Eli Lilly, GlaxoSmithKline, Merck, AstraZeneca, Janssen, Novartis, Takeda, Bayer, Pfizer. The other authors have no conflict of interest to declare.

References

    1. Passiglia F., Cinquini M., Bertolaccini L., Del Facchinetti R.M.F., Ferrara R., Franchina T., Larici A., Malapelle U., Menis J., Passaro A., et al. Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. J. Clin. Oncol. 2021;39:2575–2585. doi: 10.1200/JCO.20.02574. - DOI - PubMed
    1. De Koning H.J., van der Aalst C.M., de Jong P.A., Scholten E.T., Nackaerts K., Heuvelmans M.A., Lammers J., Weenink C., Yousaf-Khan U., Horeweg N., et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 2020;382:503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed
    1. The National Lung Screening Trial Research Team Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011;365:395–409. doi: 10.1056/NEJMoa1102873. - DOI - PMC - PubMed
    1. Serrano M.J., Garrido-Navas M.C., Diaz Mochon J.J., Cristofanilli M., Gil-Bazo I., Pauwels P., Malapelle U., Russo A., Lorente J., Ruiz-Rodriguez A., et al. Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer Discov. 2020;10:1635–1644. doi: 10.1158/2159-8290.CD-20-0466. - DOI - PubMed
    1. Ilie M., Hofman V., Long-Mira E., Selva E., Vignaud J.M., Padovani B., Mouroux J., Marquette C., Hofman P. “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE. 2014;9:e111597. doi: 10.1371/journal.pone.0111597. - DOI - PMC - PubMed